action of glp-1 agonist Frontiers Current Insights, Advantages and Challenges

Ongoing low-dose maintenance (experimental) Continuous dosing approach: Dose: 1-2mg daily OR 3-5mg 2-3x weekly Duration: Ongoing (not cycled) Goal: Maintain constant telomerase activation Status: Experimental, not from research protocols Rationale: Telomerase needs continuous activation to maintain telomere length Cyclic dosing may allow regression between cycles Low-dose continuous might provide stable benefits Similar to maintenance protocols for other peptides Continuous dosing options: Advantages of continuous: No "off" periods where benefits regress Potentially stronger cumulative anti-aging More like natural physiologic regulation Easier to stack with other peptides Disadvantages: Much higher annual cost ($1,800-3,600 vs $300-600) No long-term safety data Uncertain if better than cyclic approach Storage challenges (more reconstitution) Deviates from proven protocols Current recommendation: Stick with proven 10-day cycles for most users Consider continuous only if cyclic approach inadequate Start with standard protocol first Assess your individual response Consult with peptide-knowledgeable physician Use our peptide cycle planning guide to design your Epithalon protocol

Cartalax structure and classification Basic identity: Dipeptide: Two amino acids only Sequence: Ala-Glu (Alanine-Glutamic Acid) Also called: EDL peptide, Cartilage peptide Family: Khavinson bioregulators Target tissue: Cartilage and connective tissue Chemical structure: Molecular formula: CHNO Molecular weight: ~218 Da (very small) Just two amino acids linked Simplest possible peptide structure Easily synthesized Development history: Created by Professor Vladimir Khavinson (same as Epithalon ) St

Observed Effects of BPC-157 in Preclinical Healing Studies In laboratory and animal studies, BPC-157 has demonstrated a wide range of biological activities that may support healing and tissue regeneration

Vitamin B12 is either injected under the skin or into muscle tissue

Liu L, Feng D, Chen G, Chen M, Zheng Q, Song P, Ma Q, Zhu C, Wang R, Qi W, et al

Its a marker, not a mechanism